Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Interactome Analysis of APOBEC3B in Multiple Myeloma

Yasuhiro Kazuma, MD, Kotaro Shirakawa, MD PhD, Anamaria Daniela Sarca, MD, Yoshihito Horisawa, MD, Hirofumi Fukuda, MD, Hiroyuki Matsui, MD, Hiroyuki Yamazaki, MD, Tadahiko Matsumoto, MD, Fumiko Tanabe, Ryo Morishita, PhD, Shinji Ito, PhD, Akifumi Takaori-Kondo, MD PhD

Blood (2019) 134 (Supplement_1): 1259.

https://doi.org/10.1182/blood-2019-126856

Published: 2019

Journal Articles

MiR-300 Acts As a Tumor Supressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/β-Catenin Interplay

Giovannino Silvestri, PhD, Justin Ellis, Lorenzo Stramucci, PhD, Jason G Harb, PhD, Paolo Neviani, PhD, Guido Marcucci, MD, Denis-Claude Roy, MD, Peter Hokland, MD DMSc, Dragana Milojkovic, Alistair Reid, Jane F. Apperley, Ferenc M Livak, PhD, Maria R. Baer, MD, Rossana Trotta, PhD, Danilo Perrotti, MD PhD

Blood (2014) 124 (21): 4529.

https://doi.org/10.1182/blood.V124.21.4529.4529

Published: 2014

Journal Articles

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph + leukemias

Blood (2013) 122 (17): 3034–3044.

https://doi.org/10.1182/blood-2013-04-495374

Published: 2013

Includes: Supplemental data

Journal Articles

Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL

Christopher J Walker, Joshua J Oaks, Ramasamy Santhanam, Ph.D, Paolo Neviani, Ph.D, Jason G Harb, Ph.D, Gregory Ferenchak, Justin Ellis, Guido Marcucci, MD, Yosef Landesman, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD, PhD, Danilo Perrotti, MD, Ph.D

Blood (2012) 120 (21): 35.

https://doi.org/10.1182/blood.V120.21.35.35

Published: 2012

Journal Articles

Nuclear Export (Karyopherin) Inhibitors: A Novel Therapeutic Strategy for Treating Blast Crisis Chronic Myelogenous Leukemia (CML) and Philadelphia-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL) Through Interference with hnRNP Nucleocytoplasmic Shuttling and Rescue of Protein Phosphatase 2A (PP2A) Tumor Suppressor Activity,

Christopher J Walker, Joshua J Oaks, Ramasamy Santhanam, Ph.D, Paolo Neviani, PhD, Jason G Harb, Ph.D, Carolyn Paisie, B.S., Guido Marcucci, MD, Sharon Shacham, PhD, Michael Kauffman, MD, Ph.D., Danilo Perrotti, MD, Ph.D

Blood (2011) 118 (21): 3758.

https://doi.org/10.1182/blood.V118.21.3758.3758

Published: 2011

Journal Articles

The BCR-ABL1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML.

Jason G Harb, Paolo Neviani, Joshua J Oaks, Guido Marcucci, MD, Peter Hokland, MD, DMSC, Denis-Claude Roy, MD, FRCPC, Danilo Perrotti, MD, PhD

Blood (2010) 116 (21): 1222.

https://doi.org/10.1182/blood.V116.21.1222.1222

Published: 2010

Journal Articles

Inactivation of Pre-B Cell Receptor-Mediated Tumor Suppression by Aberrant Splicing in Ph + Acute Lymphoblastic Leukemia.

Cihangir Duy, Mieke Sprangers, Lars Klemm, Rahul R. Nahar, Daniel Nowak, MD, Giovanni Martinelli, MD, Wolf-Karsten Hofmann, Phillip H Koeffler, MD, Hassan Jumaa, Markus Müschen

Blood (2009) 114 (22): 579.

https://doi.org/10.1182/blood.V114.22.579.579

Published: 2009

Journal Articles

BCR/ABL Dosage Hierarchically and Temporally Influences hnRNP A1, hnRNP K and hnRNP E2 Expression in Hematopoietic Stem and Progenitor Cells.

Jason Harb, PhD, Paolo Neviani, PhD, Claudia Huettner, PhD, Guido Marcucci, MD, Danilo Perrotti, MD, PhD

Blood (2009) 114 (22): 191.

https://doi.org/10.1182/blood.V114.22.191.191

Published: 2009

Journal Articles

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis

Anna M. Eiring, Paolo Neviani, Ramasamy Santhanam, Joshua J. Oaks, Ji Suk Chang, Mario Notari, William Willis, Carlo Gambacorti-Passerini, Stefano Volinia, Guido Marcucci, Michael A. Caligiuri, Gustavo W. Leone, Danilo Perrotti

Blood (2008) 111 (2): 816–828.

https://doi.org/10.1182/blood-2007-05-090472

Published: 2008

Journal Articles

Identification of Alternative Splicing Changes in Erythroid Differentiation Using Human Exon Arrays.

Miki L. Yamamoto, PhD, Jeong-Ah Kang, Ph.D., Josh A. Arribere, Amittha Wickrema, Ph.D., John G. Conboy, Ph.D.

Blood (2007) 110 (11): 1707.

https://doi.org/10.1182/blood.V110.11.1707.1707

Published: 2007

Journal Articles

Requirement of the E2F3 Transcription Factor for BCR/ABL Leukemogenesis.

Anna M. Eiring, BS, Paolo Neviani, D.Sci., Ramasamy Santhanam, Ph.D., Joshua J. Oaks, B.S., Ji Suk Chang, Ph.D., Carlo Gambacorti-Passerini, MD, Stefano Volinia, MD, Guido Marcucci, MD, Michael A. Caligiuri, MD, Gustavo W. Leone, Ph.D., Danilo Perrotti, MD, Ph.D.

Blood (2007) 110 (11): 33.

https://doi.org/10.1182/blood.V110.11.33.33

Published: 2007

Journal Articles

IL-6 Enhances C-myc Translation in Myeloma Cells Via Activation of the Myc Internal Ribosomal Entry Site (IRES) and an IRES-Binding Trans Factor, hnRNP A1.

Yijiang Shi, Joseph Gera, Alan Lichtenstein

Blood (2007) 110 (11): 3514.

https://doi.org/10.1182/blood.V110.11.3514.3514

Published: 2007

Journal Articles

Modulation of Fox-Regulated Alternative Splicing Events during Erythropoiesis.

Thomas L. Gallagher, PhD, Sherry L. Gee, BA, Christina L. Schluepen, PhD, John G. Conboy, PhD

Blood (2007) 110 (11): 142.

https://doi.org/10.1182/blood.V110.11.142.142

Published: 2007

Journal Articles

Combinatorial Regulation of Protein 4.1R Exon 16 Alternative Splicing: Modulation of Fox-2 Activated Splicing by Other Intronic and Exonic Motifs.

Sherry L. Gee, Christina Schluepen, Ph.D, John G. Conboy, PhD

Blood (2006) 108 (11): 540.

https://doi.org/10.1182/blood.V108.11.540.540

Published: 2006

Journal Articles

Protein 4.1R Exon 16 Splicing Regulation by Antagonistic Activities of Fox-2 and hnRNP A1 Splicing Factors.

Christina Schluepen, PhD, Robert Lersch, PhD, Sherry L. Gee, John G. Conboy, PhD

Blood (2005) 106 (11): 804.

https://doi.org/10.1182/blood.V106.11.804.804

Published: 2005

NARROW

Interactome Analysis of APOBEC3B in Multiple Myeloma

MiR-300 Acts As a Tumor Supressor in Ph+ Progenitors By Modulating the JAK2-SET/PP2A/β-Catenin Interplay

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph + leukemias

Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL

The BCR-ABL1-Regulated hnRNP A1, hnRNP E2, and hnRNP K Are Differentially Expressed Between CD34+ and CD34+/CD38- Ph+ Cells, and After Blastic Transformation of CML.

Inactivation of Pre-B Cell Receptor-Mediated Tumor Suppression by Aberrant Splicing in Ph + Acute Lymphoblastic Leukemia.

BCR/ABL Dosage Hierarchically and Temporally Influences hnRNP A1, hnRNP K and hnRNP E2 Expression in Hematopoietic Stem and Progenitor Cells.

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis

Identification of Alternative Splicing Changes in Erythroid Differentiation Using Human Exon Arrays.

Requirement of the E2F3 Transcription Factor for BCR/ABL Leukemogenesis.

IL-6 Enhances C-myc Translation in Myeloma Cells Via Activation of the Myc Internal Ribosomal Entry Site (IRES) and an IRES-Binding Trans Factor, hnRNP A1.

Modulation of Fox-Regulated Alternative Splicing Events during Erythropoiesis.

Combinatorial Regulation of Protein 4.1R Exon 16 Alternative Splicing: Modulation of Fox-2 Activated Splicing by Other Intronic and Exonic Motifs.

Protein 4.1R Exon 16 Splicing Regulation by Antagonistic Activities of Fox-2 and hnRNP A1 Splicing Factors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only